Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indefinite Revlimid Maintenance vs Observation in MM (TT3 Follow-up)
NCT01621672Phase 3Completed
- Sponsor
- University of Arkansas
- Start
- Apr 2010
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Revlimid Maintenance with Observation (2 arms). Primary endpoint: Progression Free Survival at 2 years. Started Apr 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01621672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621672.